AOD 9604 vs semaglutide raises better questions.
A few everyday questions help separate hunger, fuel use and weight change. They also make the missing evidence easier to spot.
Keep the question small enough to answer.
We prefer a smaller question than “better metabolism”: what changed, and in whom? These distinctions help keep the answer useful.
Use
the result that fits the question
Which has stronger human weight-loss evidence?
Semaglutide showed weight loss in adults with overweight or obesity. AOD-9604’s main obesity trial failed to show a clear advantage over a dummy treatment. These were separate trials. They don’t give a direct head-to-head result.
Does metabolic health just mean losing weight?
No. Hunger, blood sugar, muscle fuel use and stored fat are different things. A weight result can’t stand in for all of them. It helps to name the change you want explained, rather than let “metabolic” do all the talking.
Store
the gaps beside the findings
Does AOD-9604 burn fat wherever it is injected?
The studies cited here don’t support fat loss at an injection site. The local fat-loss stories are anecdotal, not clinical evidence. The AOD-9604 page explains why mouse fuel-use findings and human body-fat claims need different answers.
Does combining AOD-9604 and semaglutide help?
The cited studies don’t test the pair. We have no demonstrated extra benefit or established combination safety profile from them. A positive result for semaglutide alone cannot supply either answer. Adding another name creates another question.
Respond
to what researchers actually tested
Where does MT-RNR1 fit into MOTS-c?
MT-RNR1 is a gene in mitochondrial DNA that contains the instructions for MOTS-c. Mitochondria help cells use fuel. That origin is interesting, but knowing where a peptide comes from doesn’t tell us that injecting it helps.
Do measurements in people prove MOTS-c treatment works?
No. Measuring the body’s own MOTS-c around exercise is different from giving someone MOTS-c and testing what happens. The treatment findings in that paper came from mice. The human measurements don’t establish a treatment benefit or a settled side-effect profile.
Approval and access need their own answer.
AOD-9604 and MOTS-c have no FDA approval. Their withdrawn nominations don’t mean FDA allowed pharmacies to make medicines from them. Semaglutide has approved brand medicines, while pharmacy-compounded versions have no FDA approval. Those distinctions still matter when the ingredient names look familiar.
Take a clearer question with you.
“What human result supports this for my problem?” gives a clinician something concrete to discuss. So does asking what is unknown about safety. Neither assumes that a peptide is the answer.
The comparison gives our judgement. The reading list links the sources. This guide gives no personal medical advice.